14 unknown, 11 recruiting, 6 active not recruiting, 6 completed. 17 Phase 2, 7 Not applicable, 4 Phase 1, 3 Phase 3.
Follow Immune Checkpoint Inhibitors: new trials by email Literature Review of Immune Checkpoint Inhibitors trials Research Report on Immune Checkpoint Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response lattice radiation therapy - Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-07-01 | 2026-06-26 |
| Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS Sintilimab - HIV, AIDS | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Public Health Clinical Center | 50 | 2026-05-01 | 2026-05-12 |
| DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER Prospective exploratory cohort - Endometrial Cancer, Immune Checkpoint Inhibitors | Not applicable | Recruiting | European Institute of Oncology | 510 | 2026-04-14 | 2026-07-08 |
| Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy QL1706 combined with Chemotherapy - Breast Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 40 | 2026-04-14 | 2026-09-28 |
| Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer Tislelizumab, Oxaliplatin, Capecitabine - Colonic Neoplasms, Neoadjuvant Therapy | Phase 3 | Not yet recruiting | First Affiliated Hospital of Guangxi Medical University | 94 | 2025-10-01 | 2025-08-20 |
| Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer Disitamab Vedotin, Lenvatinib, Pembrolizumab - Biliary Tract Cancer, Disitamab Vedotin | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 65 | 2025-08-30 | 2025-09-08 |
| Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2) Durvalumab, Methotrexate, Vinblastine - Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors | Phase 2 | Recruiting | AstraZeneca | 150 | 2025-05-15 | 2026-10-08 |
| Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC Sintilimab - Non-Small Cell Lung Cancer, Adjuvant Therapy | Phase 2 | Recruiting | Sichuan University | 100 | 2025-01-10 | 2026-08-05 |
| Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer Electroacupuncture combined with immunotherapy, Zilongjin tablet combined with immunotherapy, Immunotherapy - Non-Small Cell Lung Cancer, Electroacupuncture | Phase 2 / Phase 3 | Recruiting | Kong Fanming | 405 | 2025-01-01 | 2025-06-24 |
| Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma Fruquintinib - Hepatocellular Carcinoma, Immune Checkpoint Inhibitors | Phase 2 | Recruiting | Sun Yat-sen University | 36 | 2024-12-27 | 2024-12-31 |
| Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction Serplulimab Combined With Chemotherapy, Placebo combined with Chemotherapy - Stomach Neoplasms, Immune Checkpoint Inhibitors | Phase 2 | Active not recruiting | Xijing Hospital | 116 | 2024-11-15 | 2026-10-26 |
| The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer Exposure: sleep disturbance status - Lung Cancer, Sleep Disturbance | Recruiting | Second Xiangya Hospital of Central South University | 1270 | 2024-11-01 | 2025-05-16 | |
| A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy Arthritis, Polymyalgia Rheumatica | Recruiting | M.D. Anderson Cancer Center | 20 | 2024-09-11 | 2026-10-06 | |
| HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC hepatic artery infusion chemotherapy, Tyrosine kinase inhibitor (TKIs), Immune Checkpoint Inhibitors - Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor | Active not recruiting | First Hospital of China Medical University | 97 | 2024-08-16 | 2024-10-08 | |
| Fertility and Pregnancy After Avelumab Treatment Telephone interview - Gestational Trophoblastic Tumours, Immune Checkpoint Inhibitors | Not applicable | Unknown | Hospices Civils de Lyon | 50 | 2024-04-01 | 2024-03-15 |
| Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Toripalimab, Cytoreductive Nephrectomy, Axitinib - Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy | Phase 2 | Active not recruiting | RenJi Hospital | 21 | 2024-03-01 | 2026-10-27 |
| Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer Tislelizumab, Oxaliplatin, Capecitabine - Colonic Neoplasms, Neoadjuvant Therapy | Phase 2 | Active not recruiting | First Affiliated Hospital of Guangxi Medical University | 60 | 2023-11-13 | 2025-09-24 |
| Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma Cadonilimab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors | Phase 1 / Phase 2 | Unknown | Guangxi Medical University | 20 | 2023-08-01 | 2023-06-12 |
| Observational Cohort Study of Chronic Viral Infection in the Central Nervous System Immune Checkpoint Inhibitors - Progressive Multifocal Leukoencephalopathy, Immune Checkpoint Inhibitors | Recruiting | Peking Union Medical College Hospital | 66 | 2023-02-20 | 2026-04-06 | |
| Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Cadonilimab, Stereotactic radiotherapy, Renvatinib - Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus | Phase 1 / Phase 2 | Unknown | First Affiliated Hospital of Guangxi Medical University | 30 | 2023-02-02 | 2023-09-15 |
Showing 20 of 41. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Neoplasms (5) · Carcinoma, Hepatocellular (4) · Carcinoma, Renal Cell (4) · Lung Neoplasms (4) · Melanoma (4) · Uterine Cervical Neoplasms (4) · Neoplasms, Second Primary (3) · Biliary Tract Neoplasms (2) · Breast Neoplasms (2) · Colonic Neoplasms (2) · Disease Progression (2) · Endometrial Neoplasms (2) · Stomach Neoplasms (2) · Urinary Bladder Neoplasms (2)
Neoplasms by Site (29) · Neoplasms (28) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Lung Diseases (11) · Respiratory Tract Diseases (11) · Respiratory Tract Neoplasms (10) · Thoracic Neoplasms (10) · Urogenital Diseases (10) · Carcinoma (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Urogenital Neoplasms (9)
Immune Checkpoint Inhibitors (3) · Oxaliplatin (3) · tislelizumab (3) · Capecitabine (2) · Cisplatin (2) · Drug Therapy (2) · Gemcitabine (2) · Immunotherapy (2) · Radiosurgery (2) · Radiotherapy (2) · Surgical Procedures, Operative (2) · sintilimab (2) · toripalimab (2) · Albumin-Bound Paclitaxel (1) · Axitinib (1)
First Affiliated Hospital of Guangxi Medical University (3) · Lei Li (3) · Peking Union Medical College Hospital (3) · Second Xiangya Hospital of Central South University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Anhui Medical University (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Centre Hospitalier Universitaire, Amiens (1) · European Institute of Oncology (1) · First Hospital of China Medical University (1) · First People's Hospital of Hangzhou (1) · Flinders University (1) · Groupe Hospitalier Pitie-Salpetriere (1) · Guangxi Medical University (1)
China (26) · France (6) · United States (4) · Australia (2) · Italy (2) · Brazil (1) · Canada (1) · Netherlands (1) · South Korea (1) · Spain (1) · Switzerland (1)
Lei Li, M.D. (3) · Sen Zhang (2) · Abdul Naqash, MD (1) · Charles Vauchier (1) · Huaxia Yang (1) · Ilaria Betella (1) · Jiajia Chen (1) · Jianan Wang, MD, PhD (1) · Joseph B Selvanyagam, Md, PhD (1) · Jun Zhang (1) · Laura A Petrillo, MD (1) · Liu Hong, Ph.D (1) · Michael Scharl, Prof. Dr. (1) · Nathalie Beaumont (1)
PMID 10581077, PMID 11556297, PMID 12468791, PMID 12706187, PMID 15928658, PMID 21365500, PMID 21444866, PMID 21774709, PMID 22189752, PMID 22541275, PMID 23664139, PMID 24514954, PMID 24618998, PMID 24662266, PMID 24889903, PMID 25943068, PMID 26412280, PMID 26493239, PMID 26808342, PMID 27156933, PMID 28102259, PMID 28457713, PMID 28622514, PMID 29370182, PMID 29961579, PMID 30479382, PMID 30566590, PMID 30911859, PMID 30954372, PMID 32861308, PMID 38740994, PMID 39938469, PMID 41293180, PMID 42682622